PAX Therapeutics
June 22, 2026
Theater 1
Type: Company Presentation
Focus Area:
Other
PAX Therapeutics, having completed IND-enabling studies, is on the cusp of clinical trials to demonstrate optimized tendon healing by the delivery of our growth factor vector which in preclinical studies resulted in faster stronger healing with fewer adhesions. Seventeen (17) million tendon and ligament injuries occur per year in the US with a $40 Billion economic impact. Surgical repair of ruptures requires a long time to heal (note the NBA players who miss an entire season), and often results in re-ruptures, limited range-of-motion, adhesions, and pain. PAX-001 in the best animal model of tendon rupture resulted in nearly 4X stronger healing by 4 weeks and no adhesions because unlike surgery alone, the desire Type 1 collagen is laid down immediately rather than Type 3 (scar) collagen. Our initial clinical target is flexor hand tendon repairs (example: “Guacamole hand”) then will extend to other tendon and ligament rupture repairs.
Company HQ City:
East Greenwich/ moving into Ocean State Labs/ Rhode Island Life Sciences 150 Richmond Ave. Providence
Company HQ State:
Rhode Island
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
PAX-001an AAV2 vector expressing VEGF
CEO
Margaret A. Liu, MD
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
0
When you expect your next catalyst update?
Year end 2026
What is your next catalyst (value inflection) update?
IND approval and initiation of Phase I clinical trial.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}